Such binding allows for targeted delivery of an inhibitor of TGFβR1 or an agonist of TLR7/8, delaying tumor growth and extending survival of tumor-bearing mice if and only if the small molecule is delivered via PD-1-targeting nanoparticles, as free compounds and untargeted particles had no effect. This evidence concerns the gene TGFBR1 and neoplasm.